Novo Nordisk and NBA Legend Dominique Wilkins Launch My Diabetes Dream Team Sweepstakes

Wilkins is encouraging the more than 26 million Americans with type 2 diabetes1 to build their own "Diabetes Dream Team" and customize their diabetes management plan

News provided by

Novo Nordisk

Jul 21, 2015, 08:30 ET

PLAINSBORO, N.J., July 21, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, has teamed up with NBA Hall of Famer and 9-time All-Star Dominique Wilkins to help adults with type 2 diabetes take on the daily challenges of living with the disease. As part of the multiyear Diabetes Dream Team initiative, Wilkins has traveled the nation, engaging with the diabetes community. Now, the program's sweepstakes will offer one Grand Prize winner the chance to join Wilkins at a diabetes patient conference and receive a personalized support package, including time with a Certified Diabetes Educator and a personal trainer.

"After I was diagnosed with type 2 diabetes, I learned my disease could affect many areas of my health, so I built a 'Dream Team' of diabetes experts to help me," said Wilkins. "My team includes my doctors, pharmacist, diabetes educator, nutritionist, fitness trainer, and my family. While my plan is specific to me, it's a full-court approach that adults with type 2 diabetes can personalize to help manage their disease. I'm excited to be working with Novo Nordisk to motivate others to build their own 'Diabetes Dream Team.'"

Through December 31, 2015, adults with type 2 diabetes and their caregivers can enter the My Diabetes Dream Team Sweepstakes* for a chance to win access to experts and resources that will help them build their treatment plans. In addition to the Grand Prize winner, each month Wilkins will announce a Diabetes Dream Team MVP on Twitter. The MVPs will receive prize packs to help get their diabetes game plans on track. For Official Rules and to enter, visit DiabetesDreamTeam.com. Prize winners must meet eligibility criteria.

Exercise is a big part of Wilkins' diabetes management plan, but since his diagnosis he found it can be hard to find a workout routine or class that fits his needs. As part of the sweepstakes, both the Grand Prize and Monthly MVP winners will receive a gym membership and a session with a Certified Diabetes Educator and a local personal trainer to help build an exercise plan that works for them.

"Patients are at the center of what we do at Novo Nordisk," said Martin Jernigan, PhD, vice president, Diabetes Marketing at Novo Nordisk. "Through our partnership with Dominique on the Diabetes Dream Team, we hope to inspire and educate patients about the importance of a comprehensive approach to diabetes management."

Along with diet and exercise, Wilkins has been taking Victoza^® (liraglutide [rDNA origin] injection), a once-daily non-insulin injection, as part of his treatment plan for more than 2 years. "My family motivates me to be proactive about my health and work with my 'Diabetes Dream Team' to stay on track," said Wilkins, who was recently honored with the American Diabetes Association's Father of the Year Award. "I strive to stay healthy and manage my disease every day for my family. I'm here to encourage others living with diabetes to find and stick to their treatment plan to live their life to the fullest, whatever their personal drivers may be."

About Type 2 Diabetes
In the United States, more than 29 million people are affected by diabetes.¹ Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.¹ Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has tripled over the last 30 years.²

About Victoza^®
Victoza^® is a human glucagon-like peptide-1 (GLP-1) analog that was approved by the U.S. Food and Drug Administration on January 25, 2010, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

As of March 2015, Victoza^® has been commercially launched in 75 countries, including the United States, Canada, Japan, United Kingdom, Germany, France, Italy, Denmark, Hungary, Russia, India, Brazil, Mexico, Argentina, Malaysia, and China. It will be available in other markets throughout 2015.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk-us.com or follow us on Twitter.

*Certain restrictions apply. See Official Rules for entry information.

Indications and Usage

What is Victoza^®?

Victoza^® is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes, and should be used along with diet and exercise.

Victoza^® is not recommended as the first choice of medicine for treating diabetes.
It is not known if Victoza^® can be used in people who have had pancreatitis.
Victoza^® is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis.
It is not known if Victoza^® can be used with mealtime insulin.
It is not known if Victoza^® is safe and effective for use in children.

Important Safety Information

What is the most important information I should know about Victoza^®?
Victoza^® may cause serious side effects, including:

Possible thyroid tumors, including cancer. Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats and mice, Victoza^® and medicines that work like Victoza^® caused thyroid tumors, including thyroid cancer. It is not known if Victoza^® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.

Who should not use Victoza^®?
Do not use Victoza^® if:

you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
you are allergic to liraglutide or any of the ingredients in Victoza^®.

What should I tell my health care provider before using Victoza^®?
Before using Victoza^®, tell your health care provider if you:

have or have had problems with your pancreas, kidneys, or liver.
have any other medical conditions or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
are pregnant or breastfeeding or plan to become pregnant or breastfeed.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.

How should I use Victoza^®?

Do not mix insulin and Victoza^® together in the same injection.
You may give an injection of Victoza^® and insulin in the same body area (such as your stomach area), but not right next to each other.
Do not share your Victoza^® pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

What are the possible side effects of Victoza^®?
Victoza^® may cause serious side effects, including:

inflammation of your pancreas (pancreatitis). Stop using Victoza^® and call your health care provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Victoza^® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include: dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling jittery.
kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse.
serious allergic reactions. Stop using Victoza^® and get medical help right away if you have any symptoms of a serious allergic reaction including itching, rash, or difficulty breathing.

The most common side effects of Victoza^® may include headache, nausea, diarrhea, vomiting, and anti-liraglutide antibodies in your blood.

Please click here for Prescribing Information and Medication Guide.

Victoza^® is a prescription medication. Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References

Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed April 2015.
CDC. Number (in Millions) of Civilian, Noninstitutionalized Adults with Diagnosed Diabetes, United States, 1980–2011. http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htm. Accessed April 2015.

Victoza^® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Logo - http://photos.prnewswire.com/prnh/20110414/NY80976LOGO
Logo - http://photos.prnewswire.com/prnh/20150720/238370LOGO

SOURCE Novo Nordisk